Trials / Recruiting
RecruitingNCT04629326
PD-L1 Targeting Molecular Imaging of Solid Tumors
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Peking University Cancer Hospital & Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the study is to constrcut a noninvasive approach WL12 PET/CT to detect the PD-L1 expression of tumor lesions in patients with gastrointestinal tumors and to identify patients benefiting from anti-PD-1/L1 treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | 68Ga-WL12 PET/CT | WL12, labeled with PET radio-nuclide ( Ga-68 )will be used as a molecular imaging tracer for PET/CT scanning |
Timeline
- Start date
- 2021-07-20
- Primary completion
- 2024-11-01
- Completion
- 2024-11-01
- First posted
- 2020-11-16
- Last updated
- 2024-08-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04629326. Inclusion in this directory is not an endorsement.